Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 8Neoplasms 7Colorectal Neoplasms 5Recurrence 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Radiation Pneumonitis 2Peritoneal Neoplasms 2Mesothelioma, Malignant 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Patients With Any Advanced Solid Tumors 1Pancreatic Neoplasms 1Ovarian Diseases 1Oligodendroglioma 1Neuroendocrine Tumors 1Neoplasms by Site 1Neoplasm Metastasis 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × nintedanib × Clear all
NCT01024920 2021-07-19

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Boehringer Ingelheim

Phase 2 Completed
99 enrolled 45 charts
Genitourinary

Carcinoma, Renal Cell

NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1 Completed
21 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡